



Embargoed until 8am EDT/2pm CET on Friday, January 8th, 2010

Funxional Therapeutics Announces Successful Completion of the Phase I Programme of its Novel Anti-inflammatory Small Molecule, FX125L

CAMBRIDGE (UK). 8th January 2010. Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L, an orally available small molecule that belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

Following the successful completion of the single ascending dose study in July 2009, a multiple ascending dose study, in which FX125L was administered orally once-daily in healthy subjects, was conducted also in the United States. This second Phase I study confirmed the excellent safety, tolerability and PK profile of FX125L and provided data consistent with an interaction of FX125L with its target receptor. Complete results of the study will be presented in a future scientific meeting.

“The results of the multiple dose study were entirely consistent with those of the single dose study and confirmed the excellent drug-like profile of FX125L” said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. “We are now starting the preparation of the Phase II studies with FX125L in different inflammatory conditions and anticipate the initiation of these studies in the US and Europe in the second quarter of 2010”.

-ends-

About Funxional Therapeutics Ltd.

Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. Funxional is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. Funxional has research and office facilities in Cambridge.

For more information about FXT, please visit our web site (www.funxionaltherapeutics.com) or contact us by e-mail (info@funxionaltherapeutics.com).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases.

BSCIs are one of the three proprietary technology platforms in FXT’s portfolio all of which originated in the University of Cambridge, UK. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this

novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.

For enquiries regarding this press release, please contact Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics, at +44 1223 451095.